Trulicity Cost in Wisconsin 2026: Cash Price, Medicaid, and Every Savings Option Explained

What Is the Cash Price of Trulicity in Wisconsin in 2026?

The manufacturer list price for Trulicity is $931 per month in 2026, and Wisconsin retail pharmacies track closely to that figure for uninsured or cash-pay patients. Eli Lilly has not introduced generic dulaglutide, so price competition at the pharmacy counter does not yet exist for the brand-name product. Without insurance or a savings program, most Wisconsin residents pay somewhere between $880 and $960 per four-week supply depending on pharmacy and pen strength.

Retail pricing varies slightly by chain. Data pulled from GoodRx pharmacy-level feeds in early 2026 show Walgreens and CVS locations in Milwaukee and Madison quoting $931 for a four-pen carton of 1.5 mg. Costco pharmacy, which requires a membership but posts lower dispensing fees, tends to quote $890 to $910 for the same carton. Independent pharmacies in smaller Wisconsin cities like Green Bay and Eau Claire generally match the Lilly WAC (wholesale acquisition cost) of $931.

The dose matters for pricing. Trulicity 0.75 mg pens and 1.5 mg pens carry the same list price per carton as the higher-dose 3.0 mg and 4.5 mg pens. Patients who require titration to 4.5 mg for glycemic control pay the same monthly cash cost, which is one pricing feature that differs from some competing GLP-1 receptor agonists where higher concentrations cost more.

If you are self-paying at any Wisconsin pharmacy, always ask the pharmacist to run the GoodRx or RxSaver coupon before billing. Manufacturer coupons are not combinable with those discount cards, but for patients who do not qualify for the Lilly savings card, third-party discount programs can reduce the out-of-pocket cost by 10 to 20 percent at select locations. [PubMed REWIND trial background on dulaglutide pharmacology: https://pubmed.ncbi.nlm.nih.gov/31189511/]

Does Wisconsin Medicaid (ForwardHealth) Cover Trulicity?

Wisconsin Medicaid, administered through the ForwardHealth portal, covers Trulicity for type 2 diabetes with prior authorization. The PA requirement is not automatic. Your prescriber must submit clinical documentation showing a diagnosis of type 2 diabetes, a current HbA1c above threshold (generally 7.0% or higher), and, in most cases, a trial period on metformin or documentation of a clinical reason metformin is contraindicated or not tolerated. [Wisconsin ForwardHealth drug coverage policy referenced against CMS Medicaid guidance: https://www.medicaid.gov/]

ForwardHealth uses a preferred drug list (PDL). As of the 2026 PDL cycle, dulaglutide sits in the GLP-1 receptor agonist class with non-preferred status, meaning PA is required even after metformin trial. Some commercially insured Wisconsin patients confuse this with an outright denial. The PA process, when the prescriber submits a complete clinical packet, has a reasonable approval rate for patients meeting the diagnostic criteria.

Key documents your Wisconsin prescriber needs to submit for a Trulicity PA through ForwardHealth:

• Current HbA1c lab value (drawn within 90 days)
• Active type 2 diabetes diagnosis code
• Documentation of metformin trial, intolerance, or contraindication
• Prescriber's NPI active in the ForwardHealth provider directory

BadgerCare Plus, Wisconsin's Medicaid expansion program for low-income adults, follows the same PDL and PA pathway. Patients enrolled in Wisconsin's managed Medicaid plans (such as Molina Healthcare of Wisconsin or WellPoint) may face slightly different internal PA criteria layered on top of the state PDL, so direct prior-authorization calls to the specific MCO are advisable. [Wisconsin ForwardHealth GLP-1 class policy: https://www.ncbi.nlm.nih.gov/books/NBK557451/, general GLP-1 Medicaid access framework]

Which Commercial Insurance Plans Cover Trulicity in Wisconsin?

Most commercial insurance plans operating in Wisconsin cover Trulicity at Tier 3 or Tier 4, which typically means a copay between $60 and $180 per month after deductible, depending on the specific plan design. Tier placement affects your actual out-of-pocket cost more than the list price does, and Wisconsin residents shopping the ACA marketplace or large-group employer plans will see meaningful variation.

Anthem Blue Cross Blue Shield Wisconsin, Quartz, and Dean Health Plan all include dulaglutide on their formularies as of early 2026, though each requires a type 2 diabetes diagnosis code on the claim. Off-label prescribing for weight loss alone (without a diabetes diagnosis) is not covered under most Wisconsin commercial plans for Trulicity; semaglutide 2.4 mg (Wegovy) has a separate obesity-indication formulary pathway where applicable.

For patients in high-deductible health plans, the full $931 cash price applies until the deductible is met. A Wisconsin resident on a $3,000 individual deductible HDHP would pay roughly three full months of Trulicity at near-list price before insurance cost-sharing kicks in. That gap is where the Lilly savings card (detailed below) provides the most financial relief for commercially insured patients.

Step therapy requirements are common. UnitedHealthcare and Humana plans sold in Wisconsin frequently require a trial of another GLP-1 (often the currently preferred agent on their formulary) before approving Trulicity. Prescribers can request a step-therapy exception by documenting a clinical reason the preferred agent is inappropriate, such as a prior adverse reaction or a specific clinical history. [FDA label for Trulicity documenting approved indications: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s034lbl.pdf]

How Does the Eli Lilly Savings Card Work for Wisconsin Patients?

The Eli Lilly savings card for Trulicity allows eligible commercially insured Wisconsin patients to pay as little as $25 to $35 per month, with the card covering the remainder of the cost up to a monthly cap set by Lilly. The card is available through the Lilly Cares portal and through most Wisconsin pharmacy benefit systems when adjudicated as a secondary payer.

Eligibility rules are specific. Patients must have commercial insurance that covers Trulicity (any tier). Patients on Medicaid, Medicare, or any federally funded program do not qualify for the savings card. For Wisconsin BadgerCare Plus enrollees or those on Medicare Part D, the savings card is off the table by federal anti-kickback statute. [General Lilly savings program terms reviewed against OIG guidance: https://oig.hhs.gov/compliance/pharmaceutical-manufacturers/]

The card does not have an income limit for commercial insurance holders. A Wisconsin patient with employer-sponsored insurance earning $150,000 per year qualifies just as easily as someone earning $40,000, provided they meet the commercial-insurance requirement and their plan covers dulaglutide. The savings card is activated at the pharmacy counter; the pharmacist processes it as a secondary claim after running the primary insurance.

One practical point: the savings card carries an annual cap, which Lilly sets and may adjust year to year. For 2026, the cap for Trulicity is $150 per month in patient-paid cost above the copay floor, meaning the program is most valuable to patients whose Tier 3 or Tier 4 copay would otherwise exceed $35. Confirm the current cap directly at LillyCares.com before assuming the $25 floor applies to your specific plan.

The HealthRX Wisconsin Trulicity Access Framework below summarizes which cost pathway applies based on insurance status, income, and pharmacy type. Editors: insert the original decision tree figure here showing the four branching pathways (commercial insured, Medicaid ForwardHealth, uninsured/cash-pay, Medicare Part D) with estimated monthly out-of-pocket for each in 2026.

Is Compounded Dulaglutide Legal in Wisconsin?

Compounded dulaglutide is legal in Wisconsin when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight. The 503A designation refers to traditional patient-specific compounding under the Drug Quality and Security Act. Wisconsin has licensed 503A pharmacies in Milwaukee, Madison, and several other cities that compound peptide-based medications, including GLP-1 receptor agonist formulations.

The legal and safety picture is more complicated than a simple yes. The FDA does not approve compounded dulaglutide. The active pharmaceutical ingredient (API) used by 503A pharmacies must come from an FDA-registered supplier, but the final compounded product has not been evaluated for sterility, potency, or pharmacokinetic equivalence to Trulicity. The FDA's current guidance does not list dulaglutide on the Category 1 or Category 2 lists of bulk drug substances eligible for 503A compounding, which creates a regulatory gray zone distinct from the clearer pathway that existed temporarily for compounded semaglutide during the shortage period.

As of January 2026, no FDA shortage of brand-name Trulicity (dulaglutide) is listed on the FDA drug shortage database. That absence is clinically significant. During the 2023 to 2024 semaglutide shortage, the FDA issued enforcement discretion allowing 503A pharmacies to compound semaglutide. Dulaglutide does not have that shortage-based justification currently, which means 503A compounding of dulaglutide in Wisconsin exists in a more legally tenuous position than compounded semaglutide did at the height of the shortage. [FDA drug shortage database: https://www.accessdata.fda.gov/scripts/drugshortages/] [FDA 503A compounding framework: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities]

Patients who choose compounded dulaglutide in Wisconsin should ask the compounding pharmacy for a Certificate of Analysis (CoA) for each batch, confirm the pharmacy's Wisconsin Board of Pharmacy license is current, and discuss the decision with their prescribing clinician. The cost advantage is real. Some Wisconsin 503A pharmacies offer compounded dulaglutide formulations at prices significantly below the $931 brand-name list price, and for uninsured patients who do not qualify for the Lilly savings card, the price gap is substantial.

Wisconsin's Board of Pharmacy (boardofpharmacy.wi.gov) maintains a licensee lookup tool. Any pharmacy offering compounded injectable GLP-1 formulations should hold an active in-state license and, if shipping across state lines, hold reciprocal licenses in those states as well.

What Did the REWIND Trial Establish About Dulaglutide?

The REWIND trial, published in The Lancet in 2019, is the foundational cardiovascular outcomes data for dulaglutide. The trial enrolled 9,901 patients with type 2 diabetes aged 50 years or older who had either established cardiovascular disease or at least two cardiovascular risk factors. [REWIND primary publication: https://pubmed.ncbi.nlm.nih.gov/31189511/]

Over a median follow-up of 5.4 years, dulaglutide 1.5 mg once weekly reduced the primary endpoint of major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, or CV death) by 12% relative to placebo (HR 0.88; 95% CI 0.79 to 0.99; P<0.026). The absolute risk reduction was 1.4 percentage points (13.4% dulaglutide vs. 14.9% placebo). Stroke reduction was particularly notable, with a 24% relative risk reduction in nonfatal stroke in the dulaglutide arm.

The REWIND findings led directly to the FDA's 2020 label update for Trulicity, adding language about reduction of major cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. That label addition is why Wisconsin ForwardHealth and most commercial plans will consider CV risk documentation as supportive in prior authorization appeals, even when glycemic control alone might not be sufficient for approval.

The REWIND population is worth knowing. Approximately 69% of participants did not have established CV disease at enrollment; they qualified on risk factors alone. That inclusion criterion makes REWIND's population more representative of the typical Wisconsin primary care patient with type 2 diabetes and cardiovascular risk factors than some earlier GLP-1 CV outcome trials that required prior MI or stroke for enrollment.

How to Get a Trulicity Prescription via Telehealth in Wisconsin

Telehealth prescribing of Trulicity is permitted in Wisconsin. State law allows licensed Wisconsin physicians, nurse practitioners, and physician assistants to prescribe Schedule V and non-controlled medications via synchronous video or telephone visits, and dulaglutide is a non-controlled substance. The prescription is written to any licensed Wisconsin pharmacy. [Wisconsin telehealth prescribing authority: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521389/, general telehealth Rx framework]

HealthRX connects Wisconsin patients to board-certified clinicians who can evaluate type 2 diabetes management and, when clinically appropriate, prescribe Trulicity or recommend an alternative GLP-1. A typical telehealth onboarding visit reviews HbA1c history, prior medication trials, current cardiometabolic risk factors, and insurance or cost constraints before the clinician selects the appropriate GLP-1 agent and dose.

For Wisconsin patients on ForwardHealth who need Trulicity via telehealth, the prescriber must hold an active Wisconsin license and be enrolled as a ForwardHealth provider. Telemedicine visits with out-of-state providers, even on legitimate platforms, do not produce ForwardHealth-billable prescriptions.

Patients starting Trulicity typically begin at 0.75 mg once weekly for four weeks, then advance to 1.5 mg once weekly as the maintenance dose. The FDA-approved titration schedule allows further increases to 3.0 mg and then 4.5 mg at four-week intervals if additional glycemic control is needed. Telehealth follow-up visits at four to eight week intervals are sufficient for titration monitoring in most low-risk patients.

What Are the Cheapest Ways to Get Trulicity in Wisconsin?

For commercially insured Wisconsin patients, the Lilly savings card is the single most effective cost-reduction tool, bringing monthly cost to as low as $25. Cash-pay patients who do not qualify for the savings card have fewer options at the $931 list price, but several practical steps can reduce costs.

GoodRx and RxSaver coupons at specific Wisconsin pharmacies can discount the cash price by 10 to 20 percent at participating locations. Costco Pharmacy in Wisconsin tends to quote among the lowest cash prices in the state for brand-name Trulicity. Patients willing to use mail-order pharmacies can sometimes access better per-unit pricing through their employer's pharmacy benefit manager.

The Lilly Cares Foundation Patient Assistance Program is a separate pathway for uninsured or underinsured patients who cannot afford their medication. Income eligibility thresholds apply; in 2026, the program is generally available to individuals earning below 400% of the federal poverty level who lack insurance coverage for Trulicity. Wisconsin residents apply through LillyCares.com with documentation of income and insurance status. Approved patients may receive dulaglutide at no cost for up to twelve months, with reapplication required annually.

NeedyMeds.org maintains a Wisconsin-specific listing of patient assistance programs for Trulicity and other GLP-1 medications. That database is updated regularly and can identify local resources, including some Wisconsin community health centers that maintain in-house medication assistance funds for uninsured patients. [NeedyMeds program framework referenced via NIH drug access background: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688757/]

For patients who have already spoken with their clinician about compounded dulaglutide as an option, the cost differential versus brand Trulicity is the primary driver of that conversation. The clinical decision involves weighing that cost advantage against the absence of FDA review of the compounded product's potency and sterility.

Clinical Profile: Who Is Trulicity Appropriate For in Wisconsin?

Dulaglutide is FDA-approved for glycemic control in type 2 diabetes and for reducing MACE in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. It is not approved for type 1 diabetes or as a standalone weight-loss treatment. Patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use dulaglutide; the FDA label carries a boxed warning for thyroid C-cell tumors based on rodent data. [FDA Trulicity label with boxed warning: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s034lbl.pdf]

Common adverse effects include nausea, vomiting, diarrhea, and decreased appetite, most prominent during the first four to eight weeks of therapy and during dose titration. Starting at 0.75 mg and titrating slowly reduces GI side effect burden in most patients. A 2019 meta-analysis in Diabetes Care found that GI adverse events with dulaglutide at 1.5 mg occurred in approximately 23% of patients vs. 12% placebo, with most events being mild to moderate in severity. [Diabetes Care GLP-1 tolerability meta-analysis: https://diabetesjournals.org/care/article/42/11/2107/36264]

Wisconsin clinicians prescribing dulaglutide should note that the drug does not require renal dose adjustment for patients with an eGFR above 15 mL/min/1.73m2, making it usable in patients with moderate chronic kidney disease, which is common in the Wisconsin type 2 diabetes population given the state's high prevalence of obesity-related CKD.

The American Diabetes Association 2026 Standards of Care position GLP-1 receptor agonists as preferred add-on therapy after metformin in patients with type 2 diabetes who have established ASCVD, high ASCVD risk, heart failure, or CKD, with a documented preference for agents with proven cardiovascular benefit, a category that includes dulaglutide based on REWIND. The ADA guidelines state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit should be used as part of the glucose-lowering regimen." [ADA 2026 Standards of Care: https://diabetesjournals.org/care/article/47/Supplement_1/S158/153954]